Corcept Therapeutics (NASDAQ:CORT) Rating Increased to Strong-Buy at Wall Street Zen

Wall Street Zen upgraded shares of Corcept Therapeutics (NASDAQ:CORT) from a hold rating to a strong-buy rating in a research note published on Saturday morning.

CORT has been the subject of several other research reports. Piper Sandler reissued an “overweight” rating and set a $165.00 price objective (up from $88.00) on shares of Corcept Therapeutics in a report on Thursday. UBS Group set a $135.00 target price on Corcept Therapeutics in a report on Thursday, May 28th. Wolfe Research downgraded Corcept Therapeutics from a “peer perform” rating to an “underperform” rating and set a $50.00 target price on the stock. in a research report on Monday, July 27th. Truist Financial raised Corcept Therapeutics to a “strong-buy” rating in a research note on Monday, June 15th. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Corcept Therapeutics in a report on Wednesday, June 24th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $119.17.

Corcept Therapeutics Stock Performance

CORT stock opened at $114.49 on Friday. The company’s fifty day moving average price is $84.77 and its 200-day moving average price is $56.78. Corcept Therapeutics has a one year low of $28.66 and a one year high of $122.21. The company has a market capitalization of $12.38 billion, a PE ratio of 272.60 and a beta of 0.47.

Corcept Therapeutics (NASDAQ:CORT) last posted its earnings results on Wednesday, July 29th. The biotechnology company reported $0.36 earnings per share for the quarter, beating the consensus estimate of $0.02 by $0.34. The company had revenue of $256.15 million during the quarter, compared to analysts’ expectations of $221.15 million. Corcept Therapeutics had a net margin of 6.52% and a return on equity of 8.26%. Corcept Therapeutics’s quarterly revenue was up 31.7% on a year-over-year basis. During the same period last year, the company posted $0.29 earnings per share. On average, research analysts predict that Corcept Therapeutics will post 1.13 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director James N. Wilson sold 10,000 shares of Corcept Therapeutics stock in a transaction that occurred on Tuesday, June 16th. The shares were sold at an average price of $83.20, for a total transaction of $832,000.00. Following the completion of the sale, the director owned 1,094,543 shares of the company’s stock, valued at approximately $91,065,977.60. The trade was a 0.91% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Atabak Mokari sold 40,000 shares of the business’s stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $81.15, for a total value of $3,246,000.00. Following the completion of the sale, the chief financial officer owned 16,130 shares of the company’s stock, valued at $1,308,949.50. The trade was a 71.26% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 300,000 shares of company stock worth $22,088,050. 20.70% of the stock is owned by company insiders.

Institutional Investors Weigh In On Corcept Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of CORT. Torren Management LLC purchased a new stake in shares of Corcept Therapeutics in the 4th quarter worth $25,000. Advisory Services Network LLC purchased a new position in shares of Corcept Therapeutics during the third quarter valued at $25,000. Atlas Capital Advisors Inc. purchased a new position in shares of Corcept Therapeutics during the fourth quarter valued at $31,000. State of Wyoming increased its stake in shares of Corcept Therapeutics by 29.5% during the first quarter. State of Wyoming now owns 816 shares of the biotechnology company’s stock valued at $33,000 after buying an additional 186 shares during the period. Finally, Hantz Financial Services Inc. raised its holdings in shares of Corcept Therapeutics by 113.7% in the fourth quarter. Hantz Financial Services Inc. now owns 985 shares of the biotechnology company’s stock valued at $34,000 after acquiring an additional 524 shares in the last quarter. 93.61% of the stock is owned by institutional investors.

Trending Headlines about Corcept Therapeutics

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: Corcept reported second-quarter earnings of $0.36 per share, well above the $0.02 analyst consensus, while revenue reached $256.15 million versus expectations of $221.15 million. Revenue increased 31.7% year over year, helping drive the stock to a new 12-month high. Corcept Therapeutics Reaches New 12-Month High After Better-Than-Expected Earnings
• Positive Sentiment: Piper Sandler initiated or reiterated an “Overweight” rating, adding to the bullish analyst sentiment surrounding Corcept’s growth outlook. Corcept Therapeutics Earns Overweight Rating from Piper Sandler
• Positive Sentiment: HC Wainwright sharply raised its Q3 2026 EPS estimate to $0.78 from $0.34 and lifted its full-year 2026 forecast to $2.15 from $0.80. The firm maintained a “Buy” rating and a $165 price target, implying continued confidence in near-term earnings momentum.
• Neutral Sentiment: Analyst coverage remains mixed: HC Wainwright’s revised estimates imply strong 2026 earnings growth, but the firm reduced several 2027 quarterly forecasts and lowered FY2027 EPS to $3.95 from $5.38. This suggests expectations for longer-term growth have moderated.
• Negative Sentiment: Some investors may be concerned that the stock’s rapid rise has already priced in much of LIFYORLI’s potential. A recent analysis described the drug as likely to become a blockbuster but warned that Corcept’s valuation leaves limited room for disappointment. Corcept Therapeutics: LIFYORLI Is Likely a Blockbuster, But the Valuation Already Knows It

About Corcept Therapeutics

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.